SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed12d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor for additional UK reimbursement expansions and any impact on IMCIVREE prescription trends in upcoming quarterly reports.

DirectionBullish
Confidencehigh
Horizonweeks

IMCIVREE

▲ Bullish Named in this press release
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$110.68
T+0 close · Nov 4, 2026 · via day close
Latest settled
+1.34%
T+5 · $112.16 · next T+20 in 16d
Vs SPY
+2.25%
α at T+5
Latest observation
−2.64%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $110.68entry
  2. T+1 · 12d ago −5.11%α −0.70% · $105.02
  3. T+5 · 6d ago +1.34%α +2.25% · $112.16
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals announced that NICE issued positive guidance expanding IMCIVREE (setmelanotide) reimbursement to adults with Bardet-Biedl syndrome in England, Wales and Northern Ireland, building on prior pediatric coverage. This regulatory win expands the addressable patient population for IMCIVREE in the UK, supporting the company's commercial momentum in rare obesity indications.

Key Facts

  • NICE issued positive guidance for IMCIVREE (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome (BBS)
  • Expanded reimbursement allows adults to access funded treatment through the NHS in England, Wales and Northern Ireland
  • Prior NICE recommendation (May 2024) covered patients ages 6 to 17 years
  • Company market cap is $6.4B with strong institutional support

Financial Impact

Expands UK reimbursement to adult BBS population, incremental revenue potential; no specific dollar amount disclosed

revenue

Risk Factors

  • No financial terms or revenue guidance provided in the release
  • UK market represents a fraction of global opportunity; US and EU remain primary markets

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395223

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Viewing Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026